Literature DB >> 32483205

Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction.

Taher M Mandviwala1,2, Sukhdeep S Basra2, Umair Khalid1,3, June K Pickett1, Ryle Przybylowicz1,4, Tina Shah1,3, Vijay Nambi1,3, Salim S Virani1,3, Anita Deswal5,6,7.   

Abstract

BACKGROUND: Limited data exist on the association of obesity with both hospitalization and mortality in patients with heart failure with preserved ejection fraction (HFpEF), especially in the real-world ambulatory setting. We hypothesized that increasing body-mass index (BMI) in ambulatory heart failure with preserved ejection fraction would have a protective effect on these patients leading to decreased mortality and hospitalizations.
METHODS: We studied the relationship between BMI and the time to all-cause mortality, time to heart failure (HF) hospitalization, and time to all-cause hospitalization over a 2-year follow-up in a national cohort of 2501 ambulatory HFpEF patients at 153 Veterans Affairs medical centers.
RESULTS: Compared with normal BMI, overweight (HR 0.72; 95% CI 0.57-0.91), obesity class I (HR 0.59; 95% CI 0.45-0.77), obesity class II (HR 0.56; 95% CI 0.40-0.77), and obesity class III (HR 0.53; 95% CI 0.36-0.77) were associated with improved survival after adjustment for demographics and comorbidities. In contrast, the time to HF hospitalization showed an inverse relationship, with shorter time to HF hospitalization with increasing BMI compared with normal BMI; overweight (adjusted HR 1.30; 95% CI 0.88-1.90), obesity class I (HR 1.57; 95% CI 1.05-2.34), obesity class II (HR 1.79; 95% CI 1.15-2.78), and obesity class III (HR 1.96; 95% CI 1.23-3.12). However, time to first all-cause hospitalization was not significantly different by BMI groups.
CONCLUSIONS: In a large, national ambulatory HFpEF cohort, despite the presence of the obesity paradox with respect to survival, increasing BMI was independently associated with an increased risk of HF hospitalization and similar risk of all-cause hospitalization. Future longer-term prospective trials evaluating the safety and efficacy of weight loss on morbidity and mortality, in patients with severe obesity and HFpEF are needed.

Entities:  

Year:  2020        PMID: 32483205     DOI: 10.1038/s41366-020-0563-1

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  1 in total
  1 in total
  4 in total

Review 1.  Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week.

Authors:  Elissa Driggin; Laura P Cohen; Dympna Gallagher; Wahida Karmally; Thomas Maddox; Scott L Hummel; Salvatore Carbone; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2022-04-26       Impact factor: 27.203

2.  Body Mass Index, Muscle Mass, and All-Cause Mortality in Patients With Acute Heart Failure: The Obesity Paradox Revisited.

Authors:  In-Chang Hwang; Hong-Mi Choi; Yeonyee E Yoon; Jin Joo Park; Jun-Bean Park; Jae-Hyeong Park; Seung-Pyo Lee; Hyung-Kwan Kim; Yong-Jin Kim; Goo-Yeong Cho
Journal:  Int J Heart Fail       Date:  2022-04-04

3.  Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Authors:  Alice M Jackson; Pardeep S Jhund; Inder S Anand; Hans-Dirk Düngen; Carolyn S P Lam; Marty P Lefkowitz; Gerard Linssen; Lars H Lund; Aldo P Maggioni; Marc A Pfeffer; Jean L Rouleau; Jose F K Saraiva; Michele Senni; Orly Vardeny; Magnus O Wijkman; Mehmet B Yilmaz; Yoshihiko Saito; Michael R Zile; Scott D Solomon; John J V McMurray
Journal:  Eur Heart J       Date:  2021-09-21       Impact factor: 29.983

Review 4.  Implications of obesity across the heart failure continuum.

Authors:  Andrew Elagizi; Salvatore Carbone; Carl J Lavie; Mandeep R Mehra; Hector O Ventura
Journal:  Prog Cardiovasc Dis       Date:  2020-09-28       Impact factor: 8.194

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.